Connecting global biopharma to partnerships that matter.
NAPPA is a global biopharma alliance connecting companies, investors, scientists, and industry leaders across North America, Europe, Asia-Pacific, and other key innovation hubs to enable high-impact partnerships, licensing opportunities, and cross-border collaboration.
Biological Products Development from Regulatory and CMC Perspective
What regulators look for in a biologics program — regulatory strategy and CMC, read from the other side of the desk by a former FDA reviewer.
View details & register →Execution-focused support across the biopharma lifecycle.
BD & Capital
Cross-border partnerships, strategic licensing, M&A, and the creation of new ventures.
R&D Enablement
Connecting innovators with preclinical and clinical development expertise, and CRO/CDMO partners.
Market Access
Strategic guidance on U.S.–China regulatory pathways and commercialization support.
Talent & Network
High-level talent matching and a curated global industry exchange for members.
Credibility meets delivery.
Many cross-border partnerships struggle to move beyond introductory conversations. NAPPA is structured to fix that: a non-profit platform that builds trust and ecosystem connections, paired with a commercial arm that takes high-value projects across the finish line.
How it worksNon-profit platform
Ecosystem building, advisory access, and seamless resource connection across NAPPA's global network.
Commercial arm
Efficient execution of complex, high-value cross-border projects — from BD diligence through deal close.
Four pillars determine a platform's ceiling.
Scientific capability, industry experience, and capital acumen — they only deliver outcomes when they coexist. NAPPA's advisory board is structured around the four dimensions cross-border execution actually requires.
Science
Drug R&D
Industry Translation
Capital
News & Events
Open registration: biologics regulatory strategy and CMC, with Audrey Jia, October 24
Episode 4 of NAPPA Healthcare & Biopharma Insights takes the reviewer's view of biological products development — regulatory path and CMC.
Read more →Open registration: nanobodies and next-generation antibody platforms, with Weisheng Chen, September 19
Episode 3 of NAPPA Healthcare & Biopharma Insights looks past conventional IgG to single-domain antibodies and the discovery platforms behind them.
Read more →NAPPA joins the GHIS 2026 strategic partnership network
NAPPA becomes a strategic partner of the 2026 Global Healthcare Innovation Summit, held October 26–27 at the Grand Hyatt Hong Kong under the theme of reshaping healthcare innovation assets.
Read more →Join NAPPA.
Become part of an execution-driven global network bridging North American innovation with Asia-Pacific industrial scale and capital.
View membership tiers- Member-only events & roundtables
- Newsletter & deal-flow digest
- Working group participation
- Member directory access
- Everything in Individual
- Logo placement on NAPPA channels
- Partnership & sourcing introductions
- Listing in licensing/sourcing channels